For Immediate Release
Chicago, IL – July 13, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Teva Pharmaceutical Industries Ltd. (TEVA), Mylan (MYL), Momenta Pharmaceuticals, Inc. (MNTA), General Electric Company (GE) and A123 Systems Inc. (AONEQ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Another Copaxone Win for Teva
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced another favorable decision regarding its Copaxone patent. The company said that the United Kingdom High Court of Justice ruled in its favor in its patent litigation against Mylan’s (MYL) subsidiary, Generics (:UK) Limited.
Generics (:UK) Limited had asked the Court to revoke Copaxone’s European Patent (:UK) 762,888, which is scheduled to expire on May 23, 2015. Generics (:UK) Limited was also seeking to get a declaration that its generic version of Copaxone would not infringe on the ‘888 patent.
The Court not only ruled that the ‘888 patent is valid, but it also refused to state that Generics UK’s generic version of Copaxone would not infringe on it.
The favorable UK ruling comes just a few weeks after the US District Court for the Southern District of New York ruled in the company’s favor in its Copaxone patent infringement lawsuit. Teva had filed a patent infringement lawsuit against Momenta Pharmaceuticals, Inc. (MNTA)/Sandoz Inc. and Mylan/Natco Pharmaceuticals, which were looking to launch their generic versions of Copaxone.
Copaxone is approved for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Given the US court ruling, Copaxone should be protected from generic competition in the US until May 24, 2014, when the Orange Book patents are scheduled to expire. Teva believes that the protection could extend up to September 1, 2015, when the process patent is slated to expire.
The favorable rulings are a major positive for Teva. With Copaxone contributing 19.5% to total revenues in 2011, the earlier-than-expected entry of generic versions would have been a major setback for the company. Teva can now focus on extending Copaxone’s life cycle.
The company recently announced positive top-line results on Copaxone from a phase III study, GALA, which was conducted to evaluate the efficacy, safety and tolerability of Copaxone (40mg) administered thrice a week compared to placebo in patients with RRMS. The 40mg dose being evaluated in the GALA study is a higher strength compared to the 20mg dose currently available (daily injection).
Results showed that Copaxone 40mg significantly reduced disease activity. The safety and tolerability profile was also found to be favorable.
The positive rulings have removed a major overhang on the shares. We currently have a Neutral recommendation on Teva, which carries a Zacks #3 Rank (short-term Hold rating).
GE Expands Industrial Battery Business
General Electric Company (GE) intends to expand its growing industrial-battery business in order to generate $1 billion in annual revenue by the end of 2020. This expansion plan also reflects CEO Jeff Immelt’s goal of generating $500 million a year from the industrial battery business by 2015/2016.
The global battery market values approximately $50 billion, out of which the U.S. is the single biggest market in the world with a market size of $5 billion annually. Demand is expected to grow substantially in the next five years.
The industrial battery business is a market with good potential. Since customers generally order in bulk for ongoing production activity, customer acquisition is a focus area. A few good customers ensure a steady revenue stream, allowing better alignment with the fixed cost structure, which in turn allows better cost absorption. GE has already received its first order for batteries from a South African engineering company, Megatron Federal, which requires 6,000 pieces for use as backup power supplies at telecommunications sites.
GE now plans to invest $170 million in a new factory, which is up from the $100 million it initially expected to spend on the manufacture of batteries.
The new plant is located in New York and will employ approximately 450 people. For construction of the plant, GE received $15 million from New York State authorities and $5 million from local officials.
However, the new factory is not GE's only investment in battery technology. The company also has a stake in A123 Systems Inc. (AONEQ), a maker of lithium-ion batteries used in electric and hybrid cars.
General Electric currently holds a Zacks Rank of #3, which implies a short term Hold rating on the stock.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com